Janux Therapeutics (NASDAQ:JANX) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research report sent to investors on Thursday,Benzinga reports. They currently have a $100.00 price objective on the stock.

Other equities analysts have also issued research reports about the stock. Scotiabank dropped their target price on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research report on Friday, August 9th. Stifel Nicolaus started coverage on shares of Janux Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. UBS Group initiated coverage on Janux Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $69.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $63.00 target price on shares of Janux Therapeutics in a research note on Monday, August 19th. Finally, Wedbush reiterated an “outperform” rating and issued a $74.00 price objective on shares of Janux Therapeutics in a research report on Thursday, August 8th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $66.44.

Janux Therapeutics Trading Down 0.5 %

Shares of JANX stock traded down $0.29 during trading hours on Thursday, hitting $53.92. 844,960 shares of the company’s stock were exchanged, compared to its average volume of 713,695. The business’s 50 day simple moving average is $48.88 and its 200-day simple moving average is $46.35. Janux Therapeutics has a 12-month low of $5.65 and a 12-month high of $65.60. The company has a market capitalization of $2.81 billion, a PE ratio of -46.33 and a beta of 3.52.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. The business’s revenue was down 82.6% compared to the same quarter last year. Equities analysts anticipate that Janux Therapeutics will post -1.18 EPS for the current year.

Insider Buying and Selling

In other news, CEO David Alan Campbell sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $46.31, for a total transaction of $1,157,750.00. Following the sale, the chief executive officer now owns 307,054 shares in the company, valued at $14,219,670.74. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $46.31, for a total transaction of $1,157,750.00. Following the completion of the sale, the chief executive officer now directly owns 307,054 shares of the company’s stock, valued at approximately $14,219,670.74. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. purchased 1,200,000 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were acquired at an average price of $44.75 per share, with a total value of $53,700,000.00. Following the completion of the acquisition, the director now owns 9,317,246 shares of the company’s stock, valued at approximately $416,946,758.50. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 420,610 shares of company stock valued at $19,288,666 in the last three months. 29.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Janux Therapeutics

Large investors have recently bought and sold shares of the business. Plato Investment Management Ltd raised its holdings in Janux Therapeutics by 18.7% during the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after purchasing an additional 187 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares during the last quarter. Amalgamated Bank lifted its stake in Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after purchasing an additional 368 shares during the last quarter. Summit Securities Group LLC acquired a new position in shares of Janux Therapeutics during the 2nd quarter worth approximately $29,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Janux Therapeutics in the second quarter valued at about $151,000. 75.39% of the stock is currently owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.